Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The "DHT itch" is real and likely due to inflammation at the hair follicle, exacerbated by increased testosterone or androgens. Treatments mentioned include dutasteride, minoxidil, finasteride, and various topical solutions.
Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.
The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.
Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
The conversation is about hair regrowth using high-dose dutasteride, oral minoxidil, and microneedling. Users discuss seeing tiny hairs and hope they will become terminal, with advice to use derma rolling weekly for better results.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.
Age-linked hair loss is linked to disappearing collagen. Treatments discussed include minoxidil, finasteride, RU58841, tretinoin, microneedling, and collagen supplements.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
Body hair is more resilient than scalp hair due to different gene expressions and DHT sensitivity. Treatments like minoxidil and finasteride are used for hair loss, but they have varying effects on body and scalp hair.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
Cold shock therapy may promote hair growth by stimulating follicular muscles and affecting stem cells. The exact mechanisms and full range of elements involved are not yet fully understood.
The conversation discusses why some people who use hard drugs have great hair, with various opinions suggesting genetics and higher estrogen levels as possible reasons. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned.
Sons offers free Biotin capsules, Thickening Clay, or Conditioner to UK men for hair care testing. Interested individuals can apply online to receive these products.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.
Hair growth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
The conversation discusses identifying permanent hair loss and includes treatments like microneedling and biotin vitamins. The user is unsure whether the reduction in wispy hairs is due to hair revitalization or loss.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.